Related Experiment Videos
Antitumor effect of GPA1734 in rat Walker 256 carcinoma
E Missirlis1, G Karakiulakis, M E Maragoudakis
1Department of Pharmacology, University of Patras Medical School, Greece.
Abstract:
Inhibition of angiogenesis offers an alternative approach to cancer chemotherapy, since solid tumor growth has an absolute dependency on angiogenesis. We have previously shown that 8,9-dihydroxy-7-methyl-benzo [b]quinolizinium bromide (GPA1734) is a basement membrane synthesis inhibitor, and that this compound acts as an antiangiogenic agent in the chick chorioallantoic membrane. When a piece of 10 mg from a Walker 256 carcinoma was implanted into the peritoneal cavity of rats, tumor grew to about 15 g within nine days after transplant. Daily treatment of Walker 256 carcinoma bearing animals with GPA1734, at doses 10-100 mg/kg intraperitoneally, restrained tumor growth in a dose dependent manner. Macroscopic examination showed tumor cells growing in spherical masses 5-8 mm in diameter, indicative of absence of neovascularization. GPA1734 at 300 microM had no direct effect on Walker 256 carcinoma cell culture growth. The antitumor effect of this agent on Walker 256 carcinoma may be related to its antiangiogenic properties.
Insights
The novel compound GPA1734 inhibits tumor growth by preventing new blood vessel formation (angiogenesis). This antiangiogenic agent shows promise as a cancer chemotherapy alternative.
Area of Science:
- Oncology
- Cancer Research
- Angiogenesis Inhibition
Background:
- Solid tumor growth relies on angiogenesis.
- GPA1734 is a known basement membrane synthesis inhibitor with antiangiogenic properties.
- Previous studies demonstrated GPA1734's antiangiogenic effect in the chick chorioallantoic membrane model.
Purpose of the Study:
- To evaluate the anti-tumor efficacy of GPA1734.
- To investigate the role of angiogenesis inhibition in GPA1734's anti-tumor effect.
- To assess the direct impact of GPA1734 on cancer cell proliferation.
Main Methods:
- Walker 256 carcinoma cells were implanted in rats.
- Tumor-bearing rats were treated with varying doses of GPA1734.
- Tumor growth and neovascularization were assessed macroscopically.
- Walker 256 carcinoma cell cultures were treated with GPA1734 to evaluate direct cytotoxicity.
Main Results:
- GPA1734 administration significantly restrained Walker 256 carcinoma tumor growth in a dose-dependent manner.
- Macroscopic examination revealed spherical tumor masses lacking neovascularization, suggesting inhibited angiogenesis.
- GPA1734 showed no direct inhibitory effect on Walker 256 carcinoma cell culture growth at 300 microM.
Conclusions:
- GPA1734 exhibits significant anti-tumor activity against Walker 256 carcinoma in vivo.
- The anti-tumor effect of GPA1734 is likely mediated by its antiangiogenic properties, not direct cytotoxicity.
- GPA1734 represents a potential therapeutic agent for cancer chemotherapy by targeting angiogenesis.